Myosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

325 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 106
Recruiting: 58
Ph III recruiting: 6
Growth YoY: −35%
Industry share: 11%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (42)

clinicaltrialsPublishedShowing 301–325 of 325 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00060944	A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer	completed	Phase 2	271	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY	8	Sep 8, 2014	clinicaltrials
NCT00245102	Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma	completed	Phase 2	147	National Cancer Institute (NCI)NIH	1	May 23, 2014